騰盛博藥-B(02137.HK)收購HBV藥物知識產權及癌症疫苗亞太區開發權
騰盛博藥-B(02137.HK)公布,向VBI Vaccines(VBIV.US)在全球範圍內永久性購買與BRII-179 (VBI-2601)相關的任何知識產權的全部權利、所有權及權益;VBI將盡商業上合理的努力,完成與交付BRII-179 (VBI-2601)若干臨床物料及向公司轉讓BRII-179 (VBI-2601)及PreHevbri的若干物料及生產責任有關的必要業務。
同時,公司向VBI Cda收購於亞太地區(不包括日本)開發及商業化VBI-1901的獨家、可轉授、免專利權費、已繳足、永久及不可撤銷許可,惟須滿足若干條件。
公司另收購及承擔與Rehovot設施有關的若干資產及負債,且同意向SciVac授出購回權以購回與Rehovot設施有關的若干資產。
此外,作為BRII-179收購事項、技術轉讓及VBI-1901許可的代價,公司將發行承兌票據,承兌票據由抵押作為擔保。
BRII-179(VBI-2601)是一種基於重組蛋白質的新型HBV免疫治療候選藥物,公司認為其可確保用於臨床開發的BRII-179的供應不間斷,為未來商業化實現更高效的BRII-179生產,並最大限度地提高公司應佔未來現金流量;相信BRII-179在追求B型肝炎病毒(HBV)功能性治癒方面的價值,以及公司盡早開始從VBI向選定的中國合約開發及製造組織(CDMO)進行技術轉讓以控制未來潛在高需求供應的必要性。
VBI-1901是一種採用VBI的包膜病毒樣顆粒(eVLP)技術開發的新型癌症疫苗免疫治療候選藥物,公司認為其可對處於未來2b期數據結果的重要價值轉折點的資產作出機遇性的投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.